Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status by December 2, 2025 [1][3]. Company Financial Performance - Molina Healthcare reported second quarter 2025 adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [4]. - The company cut its full-year 2025 adjusted earnings per share guidance by 10.2%, revising it from at least $24.50 per share to a range of $21.50 to $22.50 per share [4]. - On July 23, 2025, Molina further reduced its full-year 2025 adjusted earnings guidance to no less than $19.00 per diluted share, representing a 13.6% cut from the previous guidance [5]. - Molina's GAAP net income for the second quarter of 2025 was reported at $4.75 per diluted share, an 8% decrease year over year, with a full-year GAAP net income guidance cut by 27% to $912 million [5]. Stock Market Reaction - Following the announcement of the second quarter results and guidance cuts, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [4]. - After the further guidance cut on July 23, 2025, Molina's stock price dropped by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025 [5]. Legal Context - The complaint against Molina alleges that the company and its executives made false or misleading statements regarding medical cost trend assumptions and the company's financial outlook [3]. - The investigation encourages investors who suffered losses to contact the firm, and it also seeks information from whistleblowers and former employees [7].

Core Viewpoint - Molina Healthcare, Inc. has faced significant challenges, including a substantial earnings miss and a downward revision of its guidance, leading to an investigation regarding potential violations of federal securities laws [1][2]. Financial Performance - Molina reported its third quarter fiscal 2025 earnings significantly below consensus expectations, with a revised full-year earnings forecast of $14 per share, down from a previous estimate of "no less than $19" made in July [2]. - The company's marketplace business performance was identified as a key factor contributing to the earnings shortfall [2]. Stock Market Reaction - Following the earnings announcement, Molina's stock price experienced a sharp decline, falling by $38.08 to open at $157.05 per share [3]. Legal Investigation - Levi & Korsinsky has initiated an investigation into Molina Healthcare for possible violations of federal securities laws, indicating potential legal challenges ahead for the company [1]. Firm Background - Levi & Korsinsky LLP is a well-established securities litigation firm with a strong track record in representing investors and has been recognized as one of the top securities litigation firms in the United States [4].

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. to secure legal counsel before the December 2, 2025 deadline for a securities class action lawsuit related to undisclosed adverse facts affecting the company's financial guidance and operations [1][5]. Group 1: Class Action Details - The class action pertains to Molina securities purchased between February 5, 2025, and July 23, 2025, with a lead plaintiff deadline set for December 2, 2025 [1][2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting the law firm [3][6]. Group 2: Allegations Against Molina Healthcare - The lawsuit alleges that Molina failed to disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - It is claimed that Molina's growth was reliant on reduced utilization of various health services, which was not communicated to investors [5]. - As a result of these undisclosed facts, Molina's financial guidance for fiscal year 2025 was likely to be significantly reduced, leading to misleading positive statements about the company's business prospects [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen has been recognized as a leading figure in the plaintiffs' bar, highlighting the firm's expertise in this area [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Molina Healthcare, Inc. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who purchased Molina securities between February 5, 2025, and July 23, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by December 2, 2025 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that Molina's management failed to disclose several material adverse facts, including issues related to medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a significant cut in financial guidance for fiscal year 2025 [5]. - The lawsuit asserts that the positive statements made by Molina's management regarding the company's business and prospects were materially misleading [5].

Core Viewpoint - Rosen Law Firm is encouraging investors of Molina Healthcare, Inc. to secure legal counsel before the December 2, 2025 deadline for a securities class action lawsuit related to undisclosed adverse facts affecting the company's financial guidance and operations [1][5]. Group 1: Class Action Details - The class action pertains to Molina securities purchased between February 5, 2025, and July 23, 2025, with a lead plaintiff deadline set for December 2, 2025 [1][2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. Group 2: Allegations Against Molina - The lawsuit alleges that Molina failed to disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a significant cut in financial guidance for fiscal year 2025 [5]. - The lawsuit asserts that the positive statements made by Molina regarding its business and prospects were materially misleading [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [4].

Core Viewpoint - Molina Healthcare, Inc. (NYSE:MOH) is facing challenges as its shares closed 7% lower, with concerns about the need for subsidies impacting investor sentiment [2]. Group 1: Company Overview - Molina Healthcare, Inc. is a healthcare insurance company that collaborates with state governments to provide healthcare services while aiming to keep costs down [3]. - The company has no exposure to tariffs, which previously contributed to a stock rally of over 4% [3]. Group 2: Market Sentiment and Investor Concerns - Investors are worried about the necessity of subsidies for Molina Healthcare, which has led to a negative perception of the stock [2]. - Jim Cramer indicated that while there are concerns, he does not consider the company completely uninvestable, suggesting potential for recovery [2]. Group 3: Comparative Investment Insights - There is a belief that certain AI stocks may offer better investment opportunities with higher returns and limited downside risk compared to Molina Healthcare [3].

Core Viewpoint - Rosen Law Firm is urging investors of Molina Healthcare, Inc. to take action before the December 2, 2025 deadline for a securities class action lawsuit related to undisclosed adverse facts affecting the company's financial guidance and operations [1][5]. Group 1: Class Action Details - The class action pertains to Molina securities purchased between February 5, 2025, and July 23, 2025, with a lead plaintiff deadline set for December 2, 2025 [1][2]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Allegations Against Molina - The lawsuit claims that Molina failed to disclose critical information regarding its medical cost trend assumptions and the dislocation between premium rates and medical costs [5]. - It is alleged that Molina's near-term growth relied on a lack of utilization of various health services, which could lead to a significant cut in financial guidance for fiscal year 2025 [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. and reminds investors of the December 2, 2025 deadline to seek the role of lead plaintiff in a federal securities class action against the company [2][5]. Group 1: Allegations Against Molina - The complaint alleges that Molina and its executives violated federal securities laws by making false or misleading statements and failing to disclose material adverse facts regarding the company's medical cost trend assumptions [5]. - Specific allegations include a dislocation between premium rates and medical costs, dependence on low utilization of various health services for near-term growth, and the likelihood of substantial cuts to financial guidance for fiscal year 2025 [5]. Group 2: Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures across all business lines [6][7]. - The company cut its full-year 2025 adjusted earnings per share guidance by 10.2%, from at least $24.50 to a range of $21.50 to $22.50, leading to a stock price drop of $6.97, or 2.9%, to close at $232.61 [7]. - On July 23, 2025, Molina further slashed its full-year 2025 earnings guidance, reporting GAAP net income of $4.75 per diluted share for the second quarter, an 8% year-over-year decrease, and cutting its full-year adjusted earnings guidance to no less than $19.00 per diluted share, resulting in a stock price decline of $32.03, or 16.84%, to close at $158.22 [8]. Group 3: Legal Proceedings and Investor Actions - The court-appointed lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [9]. - Any member of the putative class can move the court to serve as lead plaintiff or choose to remain an absent class member without affecting their ability to share in any recovery [9]. - Faruqi & Faruqi encourages anyone with information regarding Molina's conduct to contact the firm, including whistleblowers and former employees [10].

New York, New York--(Newsfile Corp. - November 11, 2025) - Levi & Korsinsky notifies investors that it has commenced an investigation of Molina Healthcare, Inc. ("Molina Healthcare, Inc.") (NYSE: MOH) concerning possible violations of federal securities laws.On October 23, 2025, Molina published its third quarter, fiscal 2025 earnings well below consensus and slashed its guidance for the third time this year, citing cost pressure and underperformance. The Company is now expecting earnings of $14 per share ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Molina Healthcare, Inc. securities between February 5, 2025, and July 23, 2025, of the December 2, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Molina securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by December 2, 2025, to serve as lead plaintiff [2]. - The lawsuit alleges that Molina failed to disclose several material adverse facts regarding its financial health and operational assumptions, which misled investors [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering hundreds of millions for investors [3]. - The firm achieved the largest securities class action settlement against a Chinese company at the time and has consistently ranked among the top firms for securities class action settlements since 2013 [3]. - In 2019, Rosen Law Firm secured over $438 million for investors, showcasing its effectiveness in litigation [3].